Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States
Số trang: 9
Loại file: pdf
Dung lượng: 958.68 KB
Lượt xem: 8
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
There is limited real-world evidence that describes patients with newly diagnosed multiple myeloma (NDMM) treated with the bortezomib, lenalidomide, and dexamethasone (VRd) triplet regimen. We evaluated patient characteristics and treatment outcomes among nontransplanted NDMM patients who received VRd as their first line of therapy (LOT) in US oncology practice settings.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Newly diagnosed multiple myeloma Real-world evidence Triplet regimen Oncology practice settings Multivariable Cox proportional hazards modelGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 169 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 139 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 110 0 0 -
12 trang 88 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 37 0 0
-
11 trang 36 0 0
-
12 trang 34 0 0